首页|匹伐他汀钙分散片在中国健康受试者的生物等效性研究

匹伐他汀钙分散片在中国健康受试者的生物等效性研究

扫码查看
目的 比较匹伐他汀钙分散片在中国健康人体内的生物利用度和生物等效性.方法 用随机、开放、自身交叉、单次给药试验设计,分别在空腹和餐后条件下,健康受试者随机交叉单剂量口服匹伐他汀钙受试制剂或参比制剂2 mg,用高效液相色谱串联质谱法(HPLC-MS/MS)测定受试者服药前后不同时间点血浆内药物浓度,用WinNonlin 7.0软件计算主要药代动力学参数,并评价2种制剂的生物等效性.结果 受试者空腹服用匹伐他汀钙受试制剂和参比制剂的Cmax分别为(47.79±23.99)和(46.03±21.82)ng·L-1,AUC0_t 分别为(96.56±42.64)和(97.96±35.40)ng·h·L-1,AUC0_∞ 分别 为(102.09±43.01)和(103.46±35.62)ng·h·L-1.受试者空腹服用匹伐他汀钙受试制剂和参比制剂的Cmax、AUC0_t和AUC0-∞的几何均值比的90%置信区间分别为 96.28%~111.16%、94.46%~101.19%和 94.77%~101.31%.受试者空腹服用匹伐他汀钙受试制剂和参比制剂的Cmax分别为(27.32±10.68)和(28.58±11.39)ng·L-1,AUC0-t 分别为(82.76±27.58)和(84.06±29.12)ng·h·L-1,AUC0-∞ 分别为(87.88±26.93)和(89.29±29.18)ng·h·L-1.受试者餐后服用匹伐他汀钙受试制剂和参比制剂的Cmax、AUC0_t和AUC0_∞的几何均值比的90%置信区间分别为87.39%~102.10%、94.62%~101.34%和94.88%~101.47%,均在80.00%~125.00%的生物等效性范围内.结论 2种匹伐他汀钙分散片在中国健康成人受试者中具有生物等效性,且安全性良好.
Bioequivalence study of pitavastatin calcium dispersible tablets in healthy Chinese volunteers
Objective To compare the bioavailability and bioequivalence of pivastatin calcium dispersive tablets in healthy Chinese subjects.Methods A single dose of pitavastatin calcium(2 mg)was orally administered to the test preparation or reference preparation under fasting and postprandial conditions,respectively.The plasma concentrations of pitavastatin calcium were measured at different time points before and after administration by high performance liquid chromatography-tandem mass spectrometry(HPLC-MS/MS).The bioequivalence of the two formulations was evaluated.Results Subjects received pitavastatin calcium test preparation and reference preparation in fasting condition,the Cmax were(47.79±23.99)and(46.03±21.82)ng·L-1;AUC0_,were(96.56±42.64)and(97.96±35.40)ng·h·L-1;AUC0_∞ were(102.09±43.01)and(103.46±35.62)ng·h·L-1,respectively.The 90%confidence intervals of the geometric mean ratios of Cmax,AUC0_t and AUC0-∞ of pitavastin-calcium test formulation and reference formulation were 96.28%-111.16%,94.46%-101.19%and 94.77%-101.31%,respectively.Subjects received pitavastatin calcium test preparation and reference preparation in fasting condition,the Cmax were(27.32±10.68)and(28.58±11.39)ng·L-1;AUC0_t were(82.76±27.58)and(84.06±29.12)ng·h·L-1;AUC0_∞ were(87.88±26.93)and(89.29±29.18)ng·h·L-1,respectively.The 90%confidence intervals of the geometric mean ratios of Cmax,AUC0_t and AUC0_∞ of the test formulation and the reference formulation of pitavastatin calcium were 87.39%-102.10%,94.62%-101.34%and 94.88%-101.47%,respectively.All of them were within the bioequivalence range of 80.00%to 125.00%.Conclusion Two pivastatin calcium dispersion tablets were bioequivalent and safe in healthy Chinese adult subjects.

pitavastatin calcium dispersible tablethigh performance liquid chromatography-tandem mass spectrometrypharmacokineticsbioequivalence

张薇、潘春苗、王小丹、胡殷、邵蓉、江波

展开 >

浙江大学医学院附属第二医院临床药理中心,浙江杭州 310009

浙江京新药业股份有限公司,浙江新昌 312500

浙江大学医学院附属第二医院护理部,浙江杭州 310009

匹伐他汀钙分散片 高效液相色谱串联质谱法 药代动力学 生物等效性

"重大新药创制"科技重大专项

2020ZX09201022

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(10)
  • 18